The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.50
Bid: 62.00
Ask: 65.00
Change: 1.00 (1.60%)
Spread: 3.00 (4.839%)
Open: 62.50
High: 63.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

NetScientific Partners with Breakout Labs

26 Mar 2014 07:00

RNS Number : 1817D
NetScientific PLC
26 March 2014
 



NetScientific Partners with Peter Thiel's Breakout Labs to Increase Support for Companies at the Forefront of Scientific Innovation

 

 

NetScientific plc (AIM:NSCI, 'NetScientific' or 'The Group'), the biomedical and healthcare technology investment group, is pleased to announce a strategic alliance with the San Francisco-based Breakout Labs, Peter Thiel's revolving philanthropic fund that supports early-stage companies working on technological breakthroughs.

 

Established by the Founder of Palantir and early investor behind PayPal and Facebook, Breakout Labs describe themselves: "Breakout Labs is not a typical foundation grant-we are a revolutionary, revolving funding model where successful projects fund the next generation of audacious scientific exploration." 

 

Breakout Labs selects and supports companies at the forefront of deep scientific innovation, providing up to $350,000 toward specific milestones, as well as mentoring and access to resources. Under the terms of the new agreement, NetScientific will invest up to $250,000 in Breakout Labs portfolio companies that fit NetScientific's investment priorities in advanced medical technologies.

 

NetScientific's board comprises former executives from leading pharmaceutical and medical technology companies. NetScientific's Richard Sykes was chairman of GSK, (GlaxoSmithKline) and Barry Wilson was international president at Medtronic. Their core investment model involves the development and fast-tracking of companies based on transformative research funded by academic institutions, governments, and science foundations.

 

"Over the past two years Breakout Labs has proven new funding models that help advance research out of the lab and into the world at large are sorely needed," said Farad Azima, CEO of NetScientific. "This partnership provides NetScientific with access to some of the most revolutionary new technologies coming out of Silicon Valley and beyond. We're impressed by Breakout Lab's ability to identify and foster revolutionary life science companies and look forward to working with them to help support a new wave of scientific innovation."

 

The first Breakout Labs company to receive a NetScientific investment is Cytovale, a pioneer in a new class of diagnostics using biomarkers based on the mechanical properties of cells. Because diseases can dramatically alter cells' physical properties, Cytovale's diagnostic platform provides a high-throughput, low cost method of detecting disease.

 

"Commercialization of breakthroughs in the hard sciences has not kept pace with the digital space - to society's detriment. This is keenly felt in the health care and life science industries where innovative ideas far too often lack access to seed-stage capital," said Lindy Fishburne, co-founder and executive director of Breakout Labs. "Inspired by the way Yuri Milner's follow-on funding supported Y Combinator companies at a critical point in their development, we are excited to partner with an investor who has a similarly bold vision. NetScientific shares our passion for helping move scientific breakthroughs out of the lab and into the economy."

 

 

For further information, please contact:

 

Liberum (Nomad & Broker)

Chris Bowman / Christopher Britton / Thomas Bective

Tel: 020 3100 2000

Bell Pottinger

Daniel de Belder

Tel: 020 7861 3232

 

Company website:www.netscientific.net

 

 

 

ABOUT NETSCIENTIFIC

NetScientific is a healthcare and life sciences company with global reach that funds and develops technologies that offer transformative benefits to peoples' lives and society through improved diagnosis, prognosis and treatment . The group is primarily focused on identifying and developing cutting edge technologies with applications in several : (i) cardiovascular; (ii) liver; (iii) cancer; (iv) metabolic; and (v) digital health.

 

ABOUT BREAKOUT LABSBreakout Labs, a program of the Thiel Foundation, is reshaping the way early-stage science and technology companies are funded. Founded in November 2011, Breakout Labs has supported 16 companies in areas ranging from food science and biomedicine to clean energy. For many of these companies, Breakout Labs was the first external investor. Breakout Labs provides up to $350,000 for companies to achieve specific milestones that are critical to their development. In addition to funding, Breakout Labs companies benefit directly from a program of mentorship and networking, with access to the Thiel Foundation's large community of investors, innovators, and entrepreneurs. Successful grantees return a capped royalty stream and a small percentage of equity in their company to Breakout Labs and thereby contribute to the next generation of scientific innovation. For more information, www.BreakoutLabs.org.

 

ABOUT THIEL FOUNDATION

The Thiel Foundation, based in San Francisco, defends and promotes freedom in all its dimensions: political, personal, and economic. The Thiel Foundation supports innovative scientific research and new technologies that empower people to improve their lives, champions organizations and individuals who expose human rights abuses and authoritarianism in all its guises, and encourages the exploration of new ideas and new spaces where people can be less reliant on government and where freedom can flourish.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRPGUBWWUPCGMA
Date   Source Headline
10th May 20249:12 amRNSPDS Biotech: Clinical trial meets study endpoints
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.